In summary, we address the therapeutic challenge of immunosuppression within the TME of advanced cervical cancer by the development of novel ADCs aimed at reprogramming the TME, with I-DXd showing particular promise due to its dual action on cancer cell ablation and pro-tumor VEGFA + TAN eradication, fostering an immunologically favorable TME. The gene discussed is VEGFA; the disease is cervical cancer.